ClinicalTrials.gg
RecruitingNCT07196501Updated Oct 22, 2026

A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

A Phase 3 interventional study of Osavampator and Placebo in Major Depressive Disorder, sponsored by Neurocrine Biosciences. Recruiting at 61 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Neurocrine Biosciences · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.
Updated Oct 22, 2026Site recruiting status changedInterventions changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
550
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Depressive Disorder, Major by Neurocrine Biosciences — 6 open to participants now, 6 under way, 5 of them phase 3. Depressive Disorder, Major · Neurocrine Biosciences.

Planned enrollment
2nd of 10
550 · median 192
Started
2025
with 5 others
Phase 3
5 of 10
5 open now
Registered
10th of 10
by date

Among the 10 studies in Depressive Disorder, Major by Neurocrine Biosciences, this one is the 2nd largest by planned enrollment, is one of 6 that started in 2025, is one of 5 in phase 3, and was the 10th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

6 of the 10 studies in Depressive Disorder, Major by Neurocrine Biosciences are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Depressive Disorder, Major by Neurocrine Biosciences, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy of osavampator (previously NBI-1065845) compared with placebo as an adjunctive treatment in delaying relapse of depressive symptoms (maintenance of effect) in participants with MDD.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Major Depressive Disorder
  • MDD
  • NBI-1065845
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participant has a primary diagnosis of recurrent MDD (moderate or severe) or persistent depressive disorder.
  • Participant has had an inadequate response to oral antidepressant treatments in the current episode of depression.
  • Participant must have been taking oral antidepressants for at least 8 weeks and is willing to continue the same oral antidepressants at the same dose and frequency of administration throughout participation in the study.
  • Total Hamilton Depression Rating Scale-17 Item (HAM-D17) score ≥22 at screening and at study baseline (Day 1).
  • Willing and able to comply with all study procedures and restrictions in the opinion of the investigator.

Key Exclusion Criteria:

  • A current or prior psychiatric disorder diagnosis in the last 1 year that was the primary focus of treatment other than MDD.
  • Are considered by the investigator to be at imminent risk of suicide or injury to self or others.
  • Participants depressive symptoms have previously demonstrated nonresponse to electroconvulsive therapy (ECT) in the current major depressive episode.

Note: Other protocol-defined Inclusion and Exclusion criteria may apply.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
550 participants (estimated)

Study arms

  • Experimental
    Open-label Treatment Period: Osavampator

    Participants will be treated with osavampator during the open-label treatment period.

    Drug: Osavampator

  • Experimental
    Randomized Double-blind Maintenance Period: Osavampator

    Participants will be randomized to receive osavampator during the randomized double-blind maintenance period.

    Drug: Osavampator

  • Experimental
    Randomized Double-blind Maintenance Period: Placebo

    Participants will be randomized to receive matching placebo during the randomized double-blind maintenance period.

    Drug: Placebo

Interventions

  • Oral tablet

    Also known as: NBI-1065845

  • DrugPlacebo

    Oral tablet

06

What researchers measure

Primary outcomes

  1. Time from Randomization to Relapse

    Time frame: From randomization to the earliest of relapse or end-of study (up to approximately 32 months)

07

Study locations

55 of 61 sites recruiting
  • Neurocrine Clinical Site
    Oceanside, California 92056, United States
    Recruiting
  • Neurocrine Clinical Site
    Orange, California 92868, United States
    Recruiting
  • Neurocrine Clinical Site
    San Jose, California 95124, United States
    Recruiting
  • Neurocrine Clinical Site
    New Haven, Connecticut 06520, United States
    Recruiting
  • Neurocrine Clinical Site
    Miami Gardens, Florida 33014, United States
    Recruiting
  • Neurocrine Clinical Site
    Orlando, Florida 32803, United States
    Recruiting
  • Neurocrine Clinical Site
    Palm Bay, Florida 32905, United States
    Recruiting
  • Neurocrine Clinical Site
    Tampa, Florida 33629, United States
    Recruiting
  • Neurocrine Clinical Site
    Iowa City, Iowa 52242, United States
    Recruiting
  • Neurocrine Clinical Site
    Marrero, Louisiana 70072, United States
    Recruiting
  • Neurocrine Clinical Site
    O'Fallon, Missouri 63368, United States
    Recruiting
  • Neurocrine Clinical Site
    Albuquerque, New Mexico 87109, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Neurocrine Clinical Site
    Glen Oaks, New York 11004, United States
    Recruiting
  • Neurocrine Clinical Site
    Charlotte, North Carolina 28211, United States
    Recruiting
  • Neurocrine Clinical Site
    Edmond, Oklahoma 73013, United States
    Recruiting
  • Neurocrine Clinical Site
    Oklahoma City, Oklahoma 73112, United States
    Recruiting
  • Neurocrine Clinical Site
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • Neurocrine Clinical Site
    Austin, Texas 78712, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Neurocrine Clinical Site
    Bellaire, Texas 77401, United States
    Recruiting
  • Neurocrine Clinical Site
    Friendswood, Texas 77546, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Neurocrine Clinical Site
    Stafford, Texas 77477, United States
    Recruiting
  • Neurocrine Clinical Site
    Wichita Falls, Texas 76309, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Neurocrine Clinical Site
    Draper, Utah 84020, United States
    Recruiting
  • Neurocrine Clinical Site
    Roanoke, Virginia 24018, United States
    Recruiting
  • Neurocrine Clinical Site
    Carlton, Victoria 3053, Australia
    Recruiting
  • Neurocrine Clinical Site
    Melbourne, Victoria 3004, Australia
    Recruiting
  • Neurocrine Clinical Site
    Parkville, Victoria 3050, Australia
    Recruiting
  • Neurocrine Clinical Site
    Sofia, 1303, Bulgaria
    Recruiting
  • Neurocrine Clinical Site
    Sofia, 1408, Bulgaria
    Recruiting
  • Neurocrine Clinical Site
    Sofia, 1510, Bulgaria
    Recruiting
  • Neurocrine Clinical Site
    Sofia, 1680, Bulgaria
    Recruiting
  • Neurocrine Clinical Site
    Calgary, Alberta T2N 2T9, Canada
    Recruiting
  • Neurocrine Clinical Site
    North Vancouver, British Columbia V7P 2T4, Canada
    Recruiting
  • Neurocrine Clinical Site
    Kingston, Ontario K7L 4X3, Canada
    Recruiting
  • Neurocrine Clinical Site
    Sherbrooke, Quebec J1L 0H8, Canada
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Neurocrine Clinical Site
    Toronto, M5H 1A1, Canada
    Recruiting
  • Neurocrine Clinical Site
    Tallinn, 10138, Estonia
    Recruiting
  • Neurocrine Clinical Site
    Tallinn, 11315, Estonia
    Recruiting
  • Neurocrine Clinical Site
    Tartu, 50417, Estonia
    Recruiting
  • Neurocrine Clinical Site
    Milan, 20127, Italy
    Withdrawn

    Not enrolling at this site — choose another above.

  • Neurocrine Clinical Site
    Roma, 168, Italy
    Recruiting
  • Neurocrine Clinical Site
    Rome, 168, Italy
    Recruiting
  • Neurocrine Clinical Site
    Torino, 10126, Italy
    Recruiting
  • Neurocrine Clinical Site
    Bialystok, 15-879, Poland
    Recruiting
  • Neurocrine Clinical Site
    Bydgoszcz, 85-794, Poland
    Recruiting
  • Neurocrine Clinical Site
    Gdansk, 80-283, Poland
    Recruiting
  • Neurocrine Clinical Site
    Belgrade, 11000, Serbia
    Recruiting
  • Neurocrine Clinical Site
    Kovin, 26220, Serbia
    Recruiting
  • Neurocrine Clinical Site
    Kragujevac, 34000, Serbia
    Recruiting
  • Neurocrine Clinical Site
    Ansan-si, Gyeonggi-do 15355, South Korea
    Recruiting
  • Neurocrine Clinical Site
    Seoul, 02841, South Korea
    Recruiting
  • Neurocrine Clinical Site
    Seoul, 06351, South Korea
    Recruiting
  • Neurocrine Clinical Site
    Seoul, 3181, South Korea
    Recruiting
  • Neurocrine Clinical Site
    Alcorcón, Madrid 28922, Spain
    Recruiting
  • Neurocrine Clinical Site
    Barcelona, 08025, Spain
    Recruiting
  • Neurocrine Clinical Site
    Barcelona, 08035, Spain
    Recruiting
  • Neurocrine Clinical Site
    Barcelona, 08036, Spain
    Recruiting
  • Neurocrine Clinical Site
    Keelung, 204, Taiwan
    Recruiting
  • Neurocrine Clinical Site
    Taipei, 10449, Taiwan
    Recruiting
  • Neurocrine Clinical Site
    Taipei, 110, Taiwan
    Recruiting
  • Neurocrine Clinical Site
    Taipei, 11217, Taiwan
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jul 2028, 35 months after the start.

Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's planned 35 months is above that.

Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2025
First posted
Sep 29, 2025
StartActual
Aug 18, 2025
Primary completionEst.
Jul 2028
CompletionEst.
Jul 2028
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added. 3 sites changed recruiting status (3 now active, not recruiting)
Show 3 sites
  • Neurocrine Clinical Site · Albuquerque, United StatesRecruiting→Active, not recruiting
  • Neurocrine Clinical Site · Wichita Falls, United StatesRecruiting→Active, not recruiting
  • Neurocrine Clinical Site · Sherbrooke, CanadaRecruiting→Active, not recruiting
Show site
  • Neurocrine Clinical Site · Barcelona, Spain
Oct 22, 2026
Interventions
Changed NBI-1065845→Osavampator. Arm changed Open-label Treatment Period: NBI-1065845→Open-label Treatment Period: Osavampator; Randomized Double-blind Maintenance Period: NBI-1065845→Randomized Double-blind Maintenance Period: Osavampator
Oct 22, 2026
Title
A Study to Evaluate the Maintenance Effect of NBI-1065845Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    1 site added. 3 sites changed recruiting status (3 now active, not recruiting)
    Show 3 sites
    • Neurocrine Clinical Site · Albuquerque, United StatesRecruiting→Active, not recruiting
    • Neurocrine Clinical Site · Wichita Falls, United StatesRecruiting→Active, not recruiting
    • Neurocrine Clinical Site · Sherbrooke, CanadaRecruiting→Active, not recruiting
    Show site
    • Neurocrine Clinical Site · Barcelona, Spain
    Interventions Changed NBI-1065845→Osavampator. Arm changed Open-label Treatment Period: NBI-1065845→Open-label Treatment Period: Osavampator; Randomized Double-blind Maintenance Period: NBI-1065845→Randomized Double-blind Maintenance Period: Osavampator
    Title A Study to Evaluate the Maintenance Effect of NBI-1065845Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07196501
Responsible party
Sponsor
First posted
Sep 29, 2025
Start date
Aug 18, 2025
Primary completion
Jul 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Oct 22, 2026

Study contacts

Neurocrine Medical Information Call Center
Contact
medinfo@neurocrine.com
1-877-641-3461
Clinical Development Lead
study director · Neurocrine Biosciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osavampator

Start the discussion